BioPharmSignal logoBioPharmSignal

Biotech News

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress

Atara Biotherapeutics, Inc. (ATRA)Atara Biotherapeutics, Inc.2026-06-25 13:46 ESTEarnings

ATRA (ATRA) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is atra.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

ATRAAtara Biotherapeutics, Inc.2026-06-25 13:46 EST

Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

ATRAAtara Biotherapeutics, Inc.2026-06-25 13:46 EST

Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

ATRAAtara Biotherapeutics, Inc.2026-06-25 13:46 EST

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

ATRAAtara Biotherapeutics, Inc.2026-06-25 13:46 EST

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

ATRAAtara Biotherapeutics, Inc.2026-06-25 13:46 EST

Atara Biotherapeutics Announces Changes to Its Board of Directors

ATRAAtara Biotherapeutics, Inc.2026-06-25 13:46 EST

Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress

ATRAAtara Biotherapeutics, Inc.2026-06-25 13:46 EST

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)

ATRAAtara Biotherapeutics, Inc.2026-06-25 13:46 EST

Atara Biotherapeutics Provides a Business Update

ATRAAtara Biotherapeutics, Inc.2026-06-25 13:46 EST

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

View all latest news

Atara Biotherapeutics, Inc.

Atara Biotherapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

ATRAAtara Biotherapeutics, Inc.2026-06-26 09:56 EST

Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

ATRAAtara Biotherapeutics, Inc.2026-06-26 09:56 EST

Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

ATRAAtara Biotherapeutics, Inc.2026-06-26 09:56 EST

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

ATRAAtara Biotherapeutics, Inc.2026-06-26 09:56 EST

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

ATRAAtara Biotherapeutics, Inc.2026-06-26 09:56 EST

Atara Biotherapeutics Announces Changes to Its Board of Directors

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States